Systemic Lupus Erythematosus (SLE) Cell Models for Research

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a global prevalence estimated at 3.41 million cases (WHO, 2020). The incidence varies by region, with higher rates in women of childbearing age (female-to-male ratio ~9:1). The 5-year survival rate for SLE patients is approximately 95% in developed countries (NCI, 2020), but the disease significantly impacts quality of life and is associated with increased mortality due to cardiovascular complications and infections. Key risk factors include genetic predisposition (e.g., HLA-DR2/DR3), hormonal influences, and environmental triggers such as UV light and infections.

SLE is a heterogeneous autoimmune disease characterized by loss of immune tolerance, production of autoantibodies, and multi-organ damage. It is an ideal model for studying immune dysregulation, autoantibody production, and the role of genetic variants in disease susceptibility. Public datasets such as GEO and TCGA (though TCGA is primarily for cancer) provide transcriptomic and genomic data from SLE patients, enabling identification of key pathways and potential therapeutic targets. Open questions include the molecular mechanisms driving disease flares, the role of specific genetic variants, and the development of targeted therapies.

SLE pathogenesis involves multiple interconnected pathways:

1. Type I Interferon (IFN) Signaling: Overproduction of type I IFNs (e.g., IFN-alpha) by plasmacytoid dendritic cells drives immune activation and autoantibody production.

2. B-cell Activation and Autoantibody Production: Dysregulated B-cell tolerance leads to production of anti-nuclear antibodies (ANAs) and immune complex deposition.

3. T-cell Dysregulation: Aberrant T-cell signaling (e.g., increased IL-17, decreased regulatory T cells) contributes to inflammation.

4. Apoptosis and Clearance Defects: Impaired clearance of apoptotic cells exposes self-antigens, triggering autoimmune responses.

Data from NCBI Gene and ClinVar.

Key signaling networks in SLE include:

• • Type I IFN pathway: Activation of JAK-STAT signaling via IFNAR; downstream induction of ISGs.
• • NF-kB pathway: Enhanced activation due to TNFAIP3 deficiency; promotes inflammatory cytokine production.
• • PI3K/AKT/mTOR pathway: Hyperactivation in T cells; contributes to cell survival and proliferation.
• • B-cell receptor (BCR) signaling: Enhanced signaling due to PTPN22 variants; promotes autoantibody production.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) can recapitulate immune cell interactions and are emerging as valuable models for studying SLE.

• • Spontaneous models: MRL/lpr and NZB/W F1 mice develop lupus-like disease.
• • Induced models: Pristane-induced lupus in BALB/c mice.
• • Genetically engineered mouse models (GEMMs): Knockout of genes like TNFAIP3 or overexpression of BAFF.
• • Patient-derived xenografts (PDX): Not commonly used for SLE due to immune system complexity, but humanized mice (e.g., NSG-SGM3) can be engrafted with human immune cells.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise genetic modifications, such as knockouts of disease-associated genes (e.g., TNFAIP3, IRF5) or knock-in of risk variants (e.g., PTPN22 R620W). These models are valuable for studying the functional impact of genetic variants in immune cells. Commercially available, sequence-verified gene-edited cell lines (e.g., THP-1 knockout for TNFAIP3) accelerate research by providing reproducible, validated tools. Such models are essential for drug discovery, target validation, and functional genomics.

Knockout and knock-in cell lines are used to validate the role of genes in SLE pathogenesis. For example, knocking out IRF5 in THP-1 cells reduces type I IFN responses, confirming its role in the pathway. Similarly, introducing the PTPN22 R620W variant into Jurkat cells alters T-cell receptor signaling, providing mechanistic insights.

Isogenic pairs (wild-type vs. knockout) are used in high-throughput screens to identify compounds that selectively target mutant cells. For instance, screening for inhibitors of the type I IFN pathway using IRF5 knockout cells can identify drugs that suppress IFN production. Resistance mechanisms can be studied by exposing cells to drugs and selecting for resistant clones, then identifying genetic changes.

CRISPR-based synthetic lethality screens can identify genes that are essential only in the context of specific mutations, revealing potential therapeutic targets. For example, in cells with TNFAIP3 loss, screening for genes whose knockout is lethal can identify vulnerabilities that can be exploited therapeutically.